摘要
目的观察归芪益元膏联合化疗治疗小细胞肺癌局限期气阴两虚证的临床疗效。方法将60例小细胞肺癌局限期气阴两虚证患者采用随机数字表法分为对照组和治疗组,各30例。对照组予化疗治疗,治疗组予归芪益元膏联合化疗治疗,21 d为1个疗程,共治疗4个疗程。2组治疗结束后随访12个月,比较2组的临床疗效、中位无进展生存期(m PFS)以及治疗前后的中医症状积分。结果对照组总有效率为40.00%(12/30)、总控制率为66.67%(20/30),治疗组总有效率为53.34%(16/30)、总控制率为76.67%(23/30),2组总有效率、总控制率比较差异均无统计学意义(P>0.05);治疗组m PFS为10个月,对照组为6个月,2组比较差异有统计学意义(P<0.05);治疗后2组中医症状积分均明显降低,与同组治疗前比较差异有统计学意义(P<0.05),且治疗组降低更明显,与对照组治疗后比较差异有统计学意义(P<0.05)。结论归芪益元膏联合化疗治疗小细胞肺癌局限期气阴两虚证可明显改善患者的临床症状,延长患者生存期,疗效显著,值得临床推广应用。
Objective To observe the clinical efficacy of Guiqi Yiyuan Gao(归芪益元膏)combined with chemotherapy in the treatment of small cell lung cancer(SCLC)with deficiency of both qi and yin syndrome in the limited-stage.Methods Sixty patients of SCLC with deficiency of both qi and yin syndrome in the limited-stage were divided into control group and treatment group by random number table method,with 30 cases in each group.The control group was given chemotherapy,and the treatment group was given Guiqi Yiyuan Gao combined with chemotherapy.Twenty-one days constituted 1 course of treatment,totally 4 courses of treatment.The 2 groups were followed up for 12 months after treatment.The clinical efficacy,median progression free survival(m PFS)and TCM symptom scores before and after treatment were compared between the 2 groups.Results The total effective rate of the control group was 40.00%(12/30),the total control rate was 66.67%(20/30),the total effective rate of the treatment group was 53.34%(16/30),and the total control rate was 76.67%(23/30),the total effective rate and total control rate of the 2 groups were not statistically significantly different(P>0.05).The m PFS of the treatment group was 10 months,and that of the control group was 6 months,and the difference between the 2 groups was statistically significant(P<0.05).After treatment,the TCM symptom scores of the 2 groups were significantly lower than those of the same group before treatment(P<0.05),moreover,the decrease in the treatment group was more significant,and the difference was statistically significant than that in the control group after treatment(P<0.05).Conclusion It can markedly alleviate the clinical symptoms and prolong the survival time of patients with marked curative effects to use Guiqi Yiyuan Gao combined with chemotherapy in the treatment of SCLC with deficiency of both qi and yin syndrome in the limited-stage,which is worthy of clinical promotion and application.
作者
马天星
李金田
梁建庆
李娟
王庆胜
王功臣
蔺兴遥
梁鹏
MA Tianxing;LI Jintian;LIANG Jianqing;LI Juan;WANG Qingsheng;WANG Gongchen;LIN Xingyao;LIANG Peng(Clinical College of TCM,Gansu University of Chinese Medicine,Lanzhou,Gansu,730101,China;Key Laboratory for Dunhuang Medicine and Transformation of Ministry of Education,Lanzhou,Gansu,730000,China;College of Basic Medicine,Gansu University of Chinese Medicine,Lanzhou,Gansu,730101,China;Department of Oncology,Affiliated Hospital of Gansu University of Chinese Medicine,Lanzhou,Gansu,730020,China;The Second Clinical Medical College,Lanzhou University,Lanzhou,Gansu,730030,China)
出处
《甘肃中医药大学学报》
2022年第1期42-46,共5页
Journal of Gansu University of Chinese Medicine
基金
国家自然科学基金地区基金项目(81460695,82160872)
中国博士后科学基金项目(2016M602887)
甘肃省中医药研究中心开放课题(zyzx-2020-zx17)。
关键词
小细胞肺癌
归芪益元膏
化疗
中位无进展生存期
中医症状积分
临床疗效
small cell lung cancer(SCLC)
Guiqi Yiyuan Gao(归芪益元膏)
chemotherapy
median progression free survival(mPFS)
TCM symptom score
clinical efficacy
